Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2705448 | 0.60 | LPL (0.36) | HCAR3HCAR2HSD11B1CACNA1BAPBA1 | |
| SCHEMBL6889536 | 0.59 | LIPG (0.42) | HSD11B1 | |
| SCHEMBL5519630 | 0.57 | HCAR2 (0.53) | HCAR3HCAR2HSD11B1CACNA1BAPBA1 | |
| SCHEMBL10968783 | 0.55 | ALDH1A1 (0.40) | HCAR3HCAR2CACNA1BAPBA1 | |
| SCHEMBL24907177 | 0.55 | SLC6A3 (0.36) | HSD11B1 | |
| SCHEMBL20757563 | 0.55 | LIPG (0.36) | HSD11B1 | |
| SCHEMBL8783063 | 0.55 | MMP2 (0.38) | HCAR3HCAR2HSD11B1CACNA1BAPBA1 | |
| SCHEMBL17570773 | 0.54 | LMNA (0.51) | — | |
| SCHEMBL542586 | 0.54 | LMNA (0.51) | — | |
| SCHEMBL18805032 | 0.54 | HCAR3 (0.41) | HCAR3HCAR2CACNA1BAPBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1992618-B1 | POLYCYCLIC CINNAMIDE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-7973033-B2 | Multi-cyclic cinnamide derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20110112138-A1 | MULTI-CYCLIC CINNAMIDE DERIVATIVES | KIMURA TEIJI | 2011-05-12 | — | — | US | disclosed |
| US-7897632-B2 | Multi-cyclic cinnamide derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20100168095-A1 | MULTI-CYCLIC CINNAMIDE DERIVATIVES | KIMURA TEIJI | 2010-07-01 | — | — | US | disclosed |
| US-7713993-B2 | Multi-cycle cinnamide derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-05-11 | — | — | US | disclosed |
| EP-1992618-A1 | POLYCYCLIC CINNAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2008-11-19 | — | — | EP | disclosed |
| US-20070219181-A1 | Multi-cyclic cinnamide derivatives | EISAI R&D MANAGEMENT CO., LTD. | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112138-A1 | MULTI-CYCLIC CINNAMIDE DERIVATIVES | BACE1, APP, PSEN1 | HCAR3 172/4885HCAR2 78/4885HSD11B1 95/4885 |
| US-20070219181-A1 | Multi-cyclic cinnamide derivatives | BACE1, APP, PSEN1 | HCAR3 172/4885HCAR2 78/4885HSD11B1 95/4885 |
| US-20100168095-A1 | MULTI-CYCLIC CINNAMIDE DERIVATIVES | BACE1, APP, PSEN1 | HCAR3 172/4885HCAR2 78/4885HSD11B1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.